Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 951 to 975 of 2491

TitleReference numberPublishedLast updated
Implanted vagus nerve stimulation for treatment-resistant depressionIPG679
Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphomaTA641
Gilteritinib for treating relapsed or refractory acute myeloid leukaemiaTA642
Entrectinib for treating ROS1-positive advanced non-small-cell lung cancerTA643
Entrectinib for treating NTRK fusion-positive solid tumoursTA644
Spartan RX point-of-care CYP2C19 test to guide treatment in acute coronary syndromeMIB223
Healthy.io test for home testing of urine albumin to creatinine ratioMIB221
pCONUS2 Bifurcation Aneurysm Implant for complex intracranial aneurysmsMIB222
Decision making and mental capacityQS194
Transcranial magnetic stimulation for obsessive-compulsive disorderIPG676
Electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney diseaseIPG677
Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplantTA640
Renal and ureteric stonesQS195
Artificial iris insertion for acquired aniridiaIPG674
Artificial iris insertion for congenital aniridiaIPG675
Remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritisES29
Specialist neonatal respiratory care for babies born pretermQS193
CFHealthHub for managing cystic fibrosis during the COVID-19 pandemicMIB219
Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancerTA638
Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancerTA639
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal)TA634
Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal)TA635
Eculizumab for treating refractory myasthenia gravis (terminated appraisal)TA636
Ranibizumab for treating diabetic retinopathy (terminated appraisal)TA637
Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasiaMTG49

Results per page

  1. 10
  2. 25
  3. 50
  4. All